FRE logo

Firebrick Pharma Limited Stock Price

ASX:FRE Community·AU$15.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

FRE Share Price Performance

AU$0
-0.05 (-100.00%)
AU$0
-0.05 (-100.00%)
Price AU$0

FRE Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
0 Rewards

Firebrick Pharma Limited Key Details

AU$515.5k

Revenue

AU$188.6k

Cost of Revenue

AU$326.9k

Gross Profit

AU$3.0m

Other Expenses

-AU$2.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.011
63.41%
-511.04%
0%
View Full Analysis

About FRE

Founded
2012
Employees
n/a
CEO
Peter Molloy
WebsiteView website
firebrickpharma.com

Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Recent FRE News & Updates

Recent updates

No updates